TGTatevik Ahurikovna Greyan

Tatevik Ahurikovna Greyan

*This is an algorithmically generated author record based on publicly available information.

Tatevik Ahurikovna Greyan has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Experience with the use of trastuzumab deruxtecan in real-world clinical practice: data from Clinical Oncology Dispensary no. 1 (Krasnodar) and Federal Scientific Clinical Center of the fMBA of Russia

    by M. Yu. Mostovoy, S. V. Sharov, E. V. Lymar, A. G. Onishchenko, J. A. Bat, A. S. Melnikova, G. G. Lisachenko, A. G. Kedrova, T. A. Greyan, М. Ю. Мостовой, et al.

    This article presents a systematic review of international and domestic experience with the use of trastuzumab deruxtecan in patients with HER2-positive and HER2-low metastatic breast cancer. Based on an analysis of key registration studies (DESTINY-Breast01, -03, -04), and confirmatory clinical trials (DESTINY-Breast02, -12) and real-world clinical practice data from the Clinical Oncology Dispensary No. 1 (Krasnodar) (n = 22) and Federal Scientific Clinical Center of the Federal Medical and Biological Agency of Russia (n = 6), the article summarizes the specifics of drug administration in the Russian healthcare setting, its efficacy profile, and manageable toxicity. A clinical case of a patient with HER2-positive mBC and brain metastases is described in detail, demonstrating long-term disease control (more than 15 months) with trastuzumab deruxtecan therapy in the second line after progression during treatment with a combination of trastuzumab, pertuzumab, and docetaxel. Practical recommendations for clinicians on monitoring the key adverse event – interstitial lung disease and pneumonitis – have been formulated.

  • Open Access

    The CA-62 marker in a program of screening aimed at active detection of cancer in women of high onkorisk

    by N. S. Denisova, Anna G. Kedrova, M. Yu. Kalinina, T. A. Greyan, D. A. Platonov

    Background. Globally, the increase in cancer rates is explained by improved diagnostic quality, an aging population, and the accumulation of unfavorable risk factors within the population. High achievements in early diagnosis of female cancer are based on expanding access to primary care and improving screening programs. Cancer is a heterogeneous group encompassing tumors with different origins, histological structures, clinical courses, and treatment outcomes, which necessitates selecting high-risk groups during routine medical examinations and periodic checkups, exploring new potential markers at this stage of population health monitoring. Aim. To investigate the role of the CA62 marker in screening programs for women at high risk of cancer. Materials and methods. The group of women with a high cancer risk was selected using automated questionnaires and amounted to 18.7 %. The main adverse risk factors were: age over 55 years combined with two external factors, including smoking/alcohol/poor diet, and physical inactivity; excess weight with a BMI 30 kg/m2; and a positive family history of cancer. Results. In 2023 and 2024, the CA-62 marker was analyzed in 1,099 women at high cancer risk. The analysis was performed using the CLIA-CA-62 chemiluminescence immunoassay (IVD). Values 5500 U/mL were found in 80 (7.27 %) women. A detailed examination of these patients revealed cancer in 5 (6.25 %) patients. Furthermore 8 (5.3 %) cases of cancer were found in the group of 150 women with reference values for the CA 62 marker. Conclusion. Thus, our analysis showed no benefit from using the CA-62 marker in screening programs for women with high-risk factors for cancer and requires further study.

  • Open Access

    Prevention of urinary tract infections after gynecological and oncogynecological surgeries

    by A. G. Kedrova, A. I. Berishvili, A. V. Gerasimov, T. A. Greyan, O. V. Zaytseva, N. S. Denisova

    Aim. To evaluate the efficacy of the dietary supplement NefroBest-N® for the prevention of urinary tract infections and inflammation after gynecological and oncogynecological surgeries.Materials and methods. The observational study included two groups of patients. The study group included 72 patients who received therapy containing the herbal preparation NefroBest-N®, 1 capsule twice daily for 30 days following surgery.The control group included 60 patients who did not receive phytoprophylaxis postoperatively. Antibiotic prophylaxis for all patients was administered with cefazolin 1 g intravenously 1 hour before surgery. Patients also underwent a standard preoperative examination, including a blood biochemistry panel (urea, creatinine, potassium, sodium, C-reactive protein), a urinalysis (presence of mucus, white blood cell count), and a urine culture.Results. Postoperative leukocyturia was more often observed in the control group – 23.3 % of cases versus 8.3 % of cases in the main group. Extended antibiotic therapy was also more common in the control group. According to the questionnaire, patients receiving NefroBest-N® scored better on their general condition than the control group (16 points versus 12 points), as well as they had less pronounced dysuric symptoms (21 points versus 29 points, respectively) and pain (12 points versus 18 points, respectively).Conclusion. The use of the herbal preparation NefroBest-N® in the postoperative period reduces the risk of developing leukocyturia and dysuric symptoms, improving the overall well-being of patients.

  • Open Access

    Outcomes of the use of epoetin alfa in preoperative therapy of malignant tumors of the female reproductive system: analysis of a series of clinical cases

    by A. G. Kedrova, T. A. Greyan

    Aim. To describe the immediate and long-term results of a series of cases of the use of epoetin alfa in preoperative therapy of malignant tumors of the female reproductive system, performed at a single clinical center.Materials and methods. The article presents the experience of treating anemia (2–3 degrees of severity) of various origins with erythropoiesis-stimulating drugs in monotherapy or in combination with iron preparations in 5 patients who sought medical care at the Federal Research and Clinical Center for Specialized Medical Care and Medical Technologies, Federal Biomedical Agency of the Russian Federation for the period from August 2024 to February 2025 due to malignant tumors of the female reproductive system of various localizations, for whom surgical treatment was indicated.Results. The mean age of patients at the time of surgery was 55.4 ± 32.5 years. The mean body mass index of patients was 25.6 ± 1.6. The mean hemoglobin level in the blood at the time of diagnosis was 78.2 ± 3 g / L. The mean duration of preoperative drug therapy was 4.4 ± 1.5 weeks, during which 2 (40 %) patients received monotherapy with epoetin alfa (40,000 IU once a week subcutaneously), 3 (60 %) patients with serum ferritin 100 ng / ml and serum transferrin iron saturation 20 % – combination therapy in combination with iron [III] hydroxide sucrose complex (intravenous jet stream 200 mg 3 times a week). The mean hemoglobin level at the time of surgery was 102.2 ± 8.5 g / L. The average postoperative hospital stay was 7.2 ± 5.5 days. No intra- or perioperative complications were observed. The average postoperative follow-up period was 7 (3–9) months, during which no recurrence of the disease was detected (0 %).Conclusion. The correction of multifactorial anemia of 2–3 degrees of severity in the preoperative period in malignant tumors of the female reproductive system using erythropoietins in monotherapy or in combination with iron preparations within a reasonable time ensures the achievement of the target hemoglobin level for subsequent surgical treatment, an acceptable quality of life for patients, and also allows to reduce the risk of perioperative complications and avoid unnecessary blood transfusions.

  • Open Access

    Mucins as a factor of carcinogenesis and a potential target for therapy of mucinous ovarian tumors

    by A. G. Kedrova, T. A. Greyan

    Mucinous ovarian carcinoma is a rare histological form of epithelial ovarian cancer. These tumors demonstrate poor objective response to standard chemotherapy regimens for epithelial ovarian cancer and PARP inhibitors maintenance therapy, resulting in short overall and disease-free survival, as well as a poor prognosis in patients with advanced disease. Macroscopically, mucinous ovarian carcinoma is characterized by the presence of mucus in the cystic cavity, consisting mainly of mucin. This review examines in detail the role of mucins in the pathogenesis and therapy of mucinous ovarian carcinoma in the context of the formation of chemoresistance and a possible point for targeted therapy.

  • Open Access

    Efficiency of Transarterial Chemoembolization with Drug-Eluting Microspheres in the Treatment of Metastatic and Primary Liver Tumors

    by Elena A. Zvezdkina, Anna G. Kedrova, Dmitry P. Lebedev, Sergey E. Krasilnikov, Tatevic A. Greyan, Dmitry N. Panchenkov, Yulia A. Stepanova, Греян Татевик Ахуриковна

    Background: Transarterial chemoembolization (TACE) is coming into use in the treatment of liver tumors, with drug-eluting microspheres as one of the technique variations. However, at the moment there are no systematic studies that would answer the questions: what is the role of the method in the treatment regimen for patients with primary and metastatic liver tumor and at what stage should it be used? Aim: to evaluate the effectiveness of transarterial chemoembolization with drug-eluting microspheres for the treatment of metastatic and primary malignant liver tumors at different stages of the disease. Methods: We performed а retrospective observational uncontrolled study of 65 patients with liver metastases (Group 1), and 10 patients with primary malignant liver tumors (Group 2), who underwent 102 operations of transarterial chemoembolization with drug-eluting microspheres. To plan transarterial chemoembolization and evaluate its effectiveness, computed tomography and magnetic resonance imaging were used every 89 weeks during the treatment. Results: After two transarterial chemoembolization controls, Group 1 included 51 responders (79%) and 14 non-responders (21%). Among the responders by the 16th week there was a decrease in the volume of the tumor mass in the liver from 12.4 [4.7; 24.6] to 5.2 cm3 [2; 15.5] for colorectal cancer, from 26 [18; 35] to 19 cm3 [13; 25] for neuroendocrine cancer, from 12 [4; 20] to 4 cm3 [0.6; 9] for adenocarcinomas of different localizations. There was no progression in Group 2, while, by week 16, there was a decrease in the tumor volume from 142 [51; 206] to 68 cm3 [23; 185] for hepatocellular carcinoma, from 465 [330; 600] to 187 cm3 [137;237] for intrahepatic cholangiocarcinoma. With repeated transarterial chemoembolization, a decrease in the volume of the tumor mass was also noted, while the time without progression decreased from 303 [170; 369] to 180 [105; 225] days in Group 1, from 266 [200; 367] to 120 [62; 215] days in Group 2. Conclusions: Transarterial chemoembolization with drug-eluting microspheres is an effective treatment for primary and metastatic liver tumors. It should be considered as a palliative therapy, which allows achieving a good antitumor response at different stages of cancer.

  • Open Access

    Evaluation of the effectiveness of transarterial chemoembolization irinotecan-loaded with drug-saturable microspheres for the treatment of patients with neuroendocrine tumors with liver metastases

    by Elena Alexandrovna Zvezdkina, Anna Genrikhovna Kedrova, Dmitry Petrovich Lebedev, Sergey E. Krasilnicov, Oleg Viktorovich Krestyaninov, Tatevik Ahurikovna Greyan, Dmitry Nikolaevich Panchenkov, Yulia Alexandrovna Stepanova, Красильников Сергей Эдуардович

    Background: Since 2021, transarterial chemoembolization of the hepatic arteries (TACE) has been included in the recommendations of professional communities for the treatment of metastases of neuroendocrine liver tumors (NEO). However, the heterogeneity of both this group of patients and types of chemoembolization with a limited range of cytostatics used in the treatment makes it difficult to analyze the data and introduce the method into the combination therapy regimens. Aim: to study the effectiveness of transarterial chemoembolization with irinotecan-loaded drug-saturable microspheres for the treatment of patients with neuroendocrine tumors with liver metastases. Methods: A retrospective, observational, uncontrolled study of 34 patients with liver metastases from neuroendocrine cancer who underwent 52 TACE with irinotecan-loaded drug-saturable microspheres. Group 1 consisted of 15 patients who already had liver metastases at the time of the primary focus detection, group 2 included 19 patients with liver metastases having appeared some time after the detection of the primary focus. To plan and evaluate the effectiveness of chemoembolization, computed tomography and magnetic resonance imaging were used every 10–15 weeks during the systemic treatment. All the patients received systemic NEO therapy before and after the embolization. Results: An increase in the progression-free time from 101 [57; 120] and 145 [89; 263] days after chemotherapy up to 300 [134; 344] and 304 [240; 342] days after TACE in groups 1 and 2, respectively, with no difference between the groups (p=0.31 and p=0.57, respectively). We did not find a linear relationship between the doubling time of the tumor and the change in the volume of the tumor lesion (R2=0.1085 and R2=0.0265 in groups 1 and 2). When comparing the intragroup scores, there was a statistically significant difference (p=0.009, p=0.046) in the tumor volume reduction and progression-free time between the patients who underwent TACE immediately and those who underwent TACE after chemotherapy. The diagnostic and angiographic images of liver metastases varied within the same organ and depended on the size of metastases. There were no adverse events after TACE. Conclusions: TACE with irinotecan-loaded drug-saturable microspheres is an effective method for the treatment of liver metastases of neuroendocrine cancer, allowing one to increase the time without progression.